Staubach, P. Et Al. 2023. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatric Allergy and Immunology , vol.34, no.7 .

Staubach, P., Alvaro-Lozano, M., ŞEKEREL, B. E., Maurer, M., Ben-Shoshan, M., Porter, M., ... Hua, E.(2023). Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatric Allergy and Immunology , vol.34, no.7.

Staubach, Petra Et Al. "Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis," Pediatric Allergy and Immunology , vol.34, no.7, 2023

Staubach, Petra Et Al. "Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis." Pediatric Allergy and Immunology , vol.34, no.7, 2023

Staubach, P. Et Al. (2023) . "Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis." Pediatric Allergy and Immunology , vol.34, no.7.

@article{article, author={Petra Staubach Et Al. }, title={Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis}, journal={Pediatric Allergy and Immunology}, year=2023}